Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Velocity Clinical Research (United States) · Novo Nordisk (Denmark) · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
283
total citations
- FWCI
- 50.65
- Percentile
- 100%
- References
- 27
Citations per year
Authors
9- JPJuan P. FríasCorresponding
Velocity Clinical Research (United States)
- SDSrikanth Deenadayalan
Novo Nordisk (Denmark)
- LELars Erichsen
Novo Nordisk (Denmark)
- FKFilip K. Knop
Steno Diabetes Center, University of Copenhagen, Gentofte Hospital
- ILIldiko Lingvay
The University of Texas Southwestern Medical Center
Topics & keywords
Topics
Keywords
- Semaglutide
- Medicine
- Type 2 diabetes
- Clinical endpoint
- Internal medicine
- Randomized controlled trial
- Adverse effect
- Intention-to-treat analysis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.